Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy

Application of the proteasome inhibitor Bortezomib for the treatment of haematopoietic malignancies such as multiple myeloma significantly improves the average overall survival of patients. However, one of the most severe side effects is the development of peripheral neuropathies caused by neurotoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: von Brzezinski, Laura, Säring, Paula, Landgraf, Peter, Cammann, Clemens, Seifert, Ulrike, Dieterich, Daniela C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Akadémiai Kiadó 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632751/
https://www.ncbi.nlm.nih.gov/pubmed/29034113
http://dx.doi.org/10.1556/1886.2017.00025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632751/
https://www.ncbi.nlm.nih.gov/pubmed/29034113
http://dx.doi.org/10.1556/1886.2017.00025

Ejemplares similares